Breaking News, Collaborations & Alliances

AxoSim Acquires Vyant Bio’s StemoniX Assets for $2.25M

Combines three leading human biomimetic organoid platform technologies for neurological drug discovery.

AxoSim, Inc., a company involved in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc., a biotechnology company, entered into a definitive agreement under which AxoSim will acquire the microBrain-associated assets of Vyant Bio’s StemoniX subsidiary. Effective immediately, AxoSim will have exclusive and sole distribution rights to market the StemoniX microBrain technology platform to pharmaceutical and biotechnology customers. Axo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters